The Heart Hospital Baylor Plano is currently the only hospital in North Texas offering the GORE® TAG® Thoracic Branch Endoprosthesis (TBE) as part of a pivotal study to evaluate its safety and efficacy. The TBE device is the first of its kind – designed for the endovascular treatment of aortic arch and descending thoracic aorta lesions in patients who are high risk for traditional surgery.
Baylor Scott & White The Heart Hospital – Plano is currently the only hospital in North Texas offering the GORE® TAG® Thoracic Branch Endoprosthesis (TBE) as part of a pivotal study to evaluate its safety and efficacy. The TBE device is the first of its kind – designed for the endovascular treatment of aortic arch and descending thoracic aorta lesions in patients who are high risk for traditional surgery.
Over the last several years, the aortic surgery program at Baylor Scott & White The Heart Hospital – Plano has grown into a high-volume Aortic Center with a reputation as a leader in the care of diseases of the aorta – across the state and beyond. With that growth has come access to innovative trials, advanced technology and, most importantly, quality outcomes.
Beyond vaccines, beyond checkpoint inhibitors, chimeric antigen receptor T-cells (CAR T-cells) are the latest form of cancer therapies aimed at reestablishing the body’s immune response to tumors. Like the Chimera of Greek mythology, a hybrid creature composed of more than one animal, CAR T-cells are molecules engineered in the laboratory using a hybrid of proteins grafted onto a patient’s T-cells. The hybrid assembly allows the CAR T-cells to carry out multiple specific functions. This engineering allows CAR T-cells to recognize specific proteins, or antigens, present on the surface of targeted cancer cells, allowing the CAR T-cells to become activated and destroy the tumor.
